<DOC>
	<DOCNO>NCT00971581</DOCNO>
	<brief_summary>Primary Objective : To confirm safety tolerability fix dose combination Non-Steroidal Anti-Inflammatory Drug ( NSAID ) , ketoprofen , associated Proton Pump Inhibitor ( PPI ) , omeprazole , Mexican patient . Secondary Objective : To confirm efficacy combination : - Relief pain ( Visual Analyzed Score ( VAS ) ) - Patients global assessment disease activity , score scale 1 ( limitation normal activity ) 5 ( inability carry normal activity )</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study With Fixed-Dose Combination ( FDC ) Ketoprofen Plus Omeprazole</brief_title>
	<detailed_description />
	<mesh_term>Ketoprofen</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Inclusion criterion : Adults suffer chronic inflammatory condition , particular , rheumatoid polyarthritis , ankylose spondylitis ( related syndrome , , Reiters syndrome , psoriatic arthritis , ) previous history risk develop NSAID associate benign gastric ulcer , duodenal ulcer gastroduodenal erosion continue treatment NSAIDs necessary . Presenting inclusion visit acute episode recent onset ( &lt; 48 hour ) define average pain within last 24 hour &gt; =50 mm Visual Analogue Scale ( VAS ) . Exclusion criterion : Hypersensitivity ketoprofen omeprazole another protonpump inhibitor excipients . Last trim pregnancy . History asthma induce administration ketoprofen similar acting substance , nonsteroidal antiinflammatory agent ( NSAIDs ) acetylsalicylic acid . Gastrointestinal disorder surgery lead impaired drug absorption . Evidence uncontrolled , unstable cardio cerebrovascular disorder , investigator 's opinion would endanger subject participate study . Serious blood coagulation disorder include use systemic anticoagulant . Positive test result H. pylorus screening . Recent endoscopy show gastric duodenal ulcer least 3 mm diameter depth . Severe hepatic failure . Severe renal failure . Severe heart failure . Patients asthma associate chronic rhinitis , chronic sinusitis and/or nasal polyposis . Active peptic ulcer . Gastrointestinal bleeding , cerebrovascular bleed active bleeding . Alcohol consumption drug abuse . Concomitant use St. Johns wort atazanavir sulphate . Concomitant use follow medication : NSAIDs include cyclooxygenase2 selective inhibitor Salicylates Corticosteroids DMARDs Antacids Histamine H2 receptor Misoprostol Other PPI Sucralfate Anticoagulants : Antiplatelet agent selective serotonin reuptake inhibitor ( SSRIs ) Lithium : Methotrexate ( dose 15 mg/week ) : Screening laboratory value ALT , AST &gt; 2 time upper limit normal . Other note specifically , screen laboratory value clinically significant investigator 's opinion would endanger subject participate study . History malignancy , treat untreated , within past 5 year , exception successfully treat basal cell squamous cell carcinoma skin . Participation study investigational treatment 8 week screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>